We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AVDL market cap is 779.56M. The company's latest EPS is USD and P/E is N/A.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 7.01M | 19.45M | 27.18M | 41.5M | 50.03M |
| Operating Income | -35.11M | -135.3M | -26.04M | -12.74M | -326k |
| Net Income | -36.27M | -28.79M | -27.34M | -13.82M | -2.63M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 59.22M | 68.14M | 53k | 0 | 27.96M |
| Operating Income | -27.17M | 4.55M | -85.55M | -98.56M | -137.85M |
| Net Income | -33.23M | 7.03M | -77.33M | -137.46M | -160.28M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 203.1M | 164.7M | 167.9M | 157.52M | 158.25M |
| Total Liabilities | 92.95M | 76.96M | 89.52M | 87.23M | 83.59M |
| Total Equity | 110.15M | 87.74M | 78.38M | 70.29M | 74.66M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 151.44M | 311.64M | 247.27M | 132.79M | 164.7M |
| Total Liabilities | 180.64M | 149.37M | 169.02M | 153.93M | 76.96M |
| Total Equity | -29.2M | 162.27M | 78.24M | -21.15M | 87.74M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -100.48M | -128.51M | -29.7M | -47.89M | -54.78M |
| Investing | -78.02M | -50.09M | 21.39M | 31.94M | 36.87M |
| Financing | 156.45M | 135.34M | 13.19M | 13.91M | 15.09M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -38.33M | -48.73M | -77.31M | -70.3M | -128.51M |
| Investing | 38.72M | -69.72M | 56.93M | 79.7M | -50.09M |
| Financing | -27k | 179.68M | 263k | 14.54M | 135.34M |
| Market Cap | 779.56M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 96.36M |
| Average Volume (1 week) | 1.01M |
| Average Volume (1 Month) | 1.35M |
| 52 Week Change | -49.50% |
| 52 Week High | 19.09 |
| 52 Week Low | 7.39 |
| Spread (Intraday) | 0.02 (0.25%) |
| Company Name | Avadel Pharmaceuticals PLC |
| Address |
10 earlsfort terrace dublin D02 T380 |
| Website | https://www.avadel.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
